Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Belite Bio, IncNASDAQ: BLTE
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization remains negative
Q3 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $117. Over 3 fiscal years it compounded at +32.8% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $29.25.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 464K USD
- Year-over-year change
- +3.3%
- 4-year CAGR
- +98.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 464K | +3.3% |
| FY2024 | 2024-12-31 | 449K | +12.5% |
| FY2023 | 2023-12-31 | 399K | +101.5% |
| FY2022 | 2022-12-31 | 198K | +560.0% |
| FY2021 | 2021-12-31 | 30K | — |
Depreciation & Amortization vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Sep 2026 depreciation & amortization of $117 is the lowest of the 6 companies compared; the peer median is $2.45M.
- Its year-over-year change of -99.9% is the lowest of 5, against a peer median of +16.3%.
- Over three fiscal years its annual growth of +32.8% compares with a peer median of +52.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $19.04M | -28.1% | +33.7% | — | |
| LTM Mar 2026 | $2.47M | -8.6% | +70.7% | 55.3% | |
| LTM Mar 2026 | $2.45M | +41.2% | -1.9% | 32.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +241.9% | +136.6% | 0.4% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K | — | — | — |
BLTEBelite Bio, Inc | LTM Sep 2026 | $117 | -99.9% | +32.8% | — |
| Peer median (excluding BLTE) | $2.45M | +16.3% | +52.2% | 32.1% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.